S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:MBRX

Moleculin Biotech (MBRX) Stock Price, News & Analysis

$5.91
+0.37 (+6.68%)
(As of 05:21 PM ET)
Today's Range
$5.18
$6.23
50-Day Range
$4.68
$10.32
52-Week Range
$4.34
$24.75
Volume
77,685 shs
Average Volume
31,254 shs
Market Capitalization
$13.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$101.67

Moleculin Biotech MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,555.8% Upside
$101.67 Price Target
Short Interest
Healthy
0.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Moleculin Biotech in the last 14 days
Based on 25 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($10.27) to ($9.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.12 out of 5 stars

Medical Sector

363rd out of 938 stocks

Pharmaceutical Preparations Industry

164th out of 433 stocks

MBRX stock logo

About Moleculin Biotech Stock (NASDAQ:MBRX)

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.

MBRX Stock Price History

MBRX Stock News Headlines

How you can target big results without spending big money!
While most folks are paying $500… $1,000… Or even MORE to trade popular stocks like Apple, Nvidia, or Microsoft… I’ve discovered a new way to tap into what could be the cheapest options on the market… I’m talking about the $0.25 Cent Trades!
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
A Preview Of Moleculin Biotech's Earnings
Moleculin Announces Reverse Stock Split
See More Headlines
Receive MBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2023
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MBRX
Fax
N/A
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$101.67
High Stock Price Target
$240.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+1,735.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-29,770,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$27.33 per share

Miscellaneous

Free Float
2,078,000
Market Cap
$12.35 million
Optionable
Not Optionable
Beta
1.98
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Walter V. Klemp (Age 64)
    Founder, Chairman, President & CEO
    Comp: $894.54k
  • Mr. Jonathan P. Foster CPA (Age 60)
    Executive VP & CFO
    Comp: $611.17k
  • Dr. Donald H. Picker Ph.D. (Age 78)
    Chief Scientific Officer
    Comp: $486.44k
  • Dr. Waldemar Priebe Ph.D.
    Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board
  • Dr. Robert C. Shepard FACP (Age 72)
    M.D., Chief Medical Officer of Annamycin
  • Dr. John Paul Waymack M.D. (Age 72)
    Sc.D., Senior Chief Medical Officer
  • Dr. Sandra L. Silberman M.D. (Age 69)
    Ph.D., Chief Medical Officer of New Products
  • Dr. Wolfram C. M. Dempke M.B.A.
    M.D., Ph.D., European Chief Medical Officer
  • Ms. Jacqueline Northcut (Age 62)
    Consultant
    Comp: $51.11k
  • Mr. Louis Ploth Jr. (Age 70)
    Independent Advisor
    Comp: $118.49k

MBRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Moleculin Biotech stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBRX shares.
View MBRX analyst ratings
or view top-rated stocks.

What is Moleculin Biotech's stock price target for 2024?

3 brokers have issued 12 month price objectives for Moleculin Biotech's stock. Their MBRX share price targets range from $20.00 to $240.00. On average, they anticipate the company's share price to reach $101.67 in the next twelve months. This suggests a possible upside of 1,555.8% from the stock's current price.
View analysts price targets for MBRX
or view top-rated stocks among Wall Street analysts.

How have MBRX shares performed in 2024?

Moleculin Biotech's stock was trading at $12.8760 at the beginning of the year. Since then, MBRX stock has decreased by 52.3% and is now trading at $6.14.
View the best growth stocks for 2024 here
.

Are investors shorting Moleculin Biotech?

Moleculin Biotech saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 2,100 shares, a drop of 98.4% from the February 29th total of 134,400 shares. Based on an average daily trading volume, of 28,800 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.1% of the shares of the stock are short sold.
View Moleculin Biotech's Short Interest
.

When is Moleculin Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our MBRX earnings forecast
.

How were Moleculin Biotech's earnings last quarter?

Moleculin Biotech, Inc. (NASDAQ:MBRX) issued its earnings results on Friday, August, 11th. The company reported ($3.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.20) by $1.20. During the same period in the prior year, the company earned ($3.60) earnings per share.

When did Moleculin Biotech's stock split?

Moleculin Biotech's stock reverse split before market open on Friday, March 22nd 2024. The 1-15 reverse split was announced on Friday, March 22nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Moleculin Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL).

Who are Moleculin Biotech's major shareholders?

Moleculin Biotech's stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (9.60%), Citadel Advisors LLC (0.19%) and Atticus Wealth Management LLC (0.17%). Insiders that own company stock include Jonathan P Foster, Robert E George and Walter V Klemp.
View institutional ownership trends
.

How do I buy shares of Moleculin Biotech?

Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MBRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners